Daurismo(glasdegib)
Daurismo (glasdegib) is a small molecule pharmaceutical. Glasdegib was first approved as Daurismo on 2018-11-21. It is used to treat myeloid leukemia acute in the USA. It has been approved in Europe to treat myeloid leukemia acute. The pharmaceutical is active against protein smoothened.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Daurismo
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| daurismo | New Drug Application | 2023-11-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| myeloid leukemia acute | — | D015470 | C92.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
GLASDEGIB MALEATE, DAURISMO, PFIZER | |||
| 2025-11-21 | ODE-224 | ||
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 4 | 6 | 3 | — | 1 | 13 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 4 | 6 | 3 | — | 1 | 13 |
| Myeloid leukemia | D007951 | — | C92 | 4 | 6 | 3 | — | 1 | 13 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 2 | 1 | — | — | 4 |
| Preleukemia | D011289 | — | — | 1 | 2 | 1 | — | — | 4 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | 1 | 1 | — | — | 3 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | 1 | 1 | — | — | 3 |
| Sarcoma | D012509 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | 2 | 2 | — | — | — | 2 |
| Bronchiolitis obliterans syndrome | D000092122 | — | — | 2 | 2 | — | — | — | 2 |
| Fasciitis | D005208 | HP_0100537 | M72.9 | 1 | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 1 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | 1 | — | — | — | 1 |
| Essential thrombocythemia | D013920 | — | D47.3 | — | 1 | — | — | — | 1 |
| Polycythemia vera | D011087 | — | D45 | — | 1 | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | — | 1 | — | — | — | 1 |
| Thrombocytosis | D013922 | HP_0001894 | D75.83 | — | 1 | — | — | — | 1 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
| Neoplasms | D009369 | — | C80 | 3 | — | — | — | — | 3 |
| Hematologic neoplasms | D019337 | — | — | 2 | — | — | — | — | 2 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Glasdegib |
| INN | glasdegib |
| Description | Glasdegib is a member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a (2R,4S)-4-{[(4-cyanophenyl)carbamoyl]amino}-1-methylpiperidin-2-yl group at position 2. It is a hedgehog signalling pathway inhibitor that acts by binding to Smoothened (SMO) receptors and blocking signal transduction (IC50 = 5 nM). It is used in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients (aged >= 75 years), or who have medical conditions that prevent the use of standard chemotherapy. It has a role as a SMO receptor antagonist, a Hedgehog signaling pathway inhibitor and an antineoplastic agent. It is a member of benzimidazoles, a member of piperidines, a member of phenylureas and a nitrile. |
| Classification | Small molecule |
| Drug class | hedgehog signaling inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1 |
Identifiers
| PDB | — |
| CAS-ID | 1095173-27-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2043437 |
| ChEBI ID | — |
| PubChem CID | 25166913 |
| DrugBank | DB11978 |
| UNII ID | K673DMO5H9 (ChemIDplus, GSRS) |
Target
Agency Approved
SMO
SMO
Organism
Homo sapiens
Gene name
SMO
Gene synonyms
SMOH
NCBI Gene ID
Protein name
protein smoothened
Protein synonyms
frizzled family member 11, Protein Gx, seven transmembrane helix receptor, smoothened homolog, smoothened, frizzled family receptor, smoothened, seven transmembrane spanning receptor
Uniprot ID
Mouse ortholog
Smo (319757)
protein smoothened (P56726)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 727 documents
View more details
Safety
Black-box Warning
Black-box warning for: Daurismo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
508 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use